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INTRODUCTION
The diagnosis of chronic thromboembolic pulmonary hy-
pertension (CTEPH) requires an objective demonstration of 
two components of the disease: pulmonary hypertension in 
haemodynamic studies of the pulmonary circulation (mean 
pulmonary arterial pressure [MPAP] ≥ 25 mm Hg) and throm-
boembolic changes in imaging studies. Although the aetiology 
and pathogenesis of CTEPH has not yet been completely 
elucidated, the association between a previous diagnosis of 
acute pulmonary embolism (APE) can be demonstrated in up 
to about 50% of the cases. CTEPH is, however, a very rare 
consequence of diagnosed and treated APE. Its incidence is 
estimated at 0.1–0.5% [1], although, according to Pengo et 
al. [2], it may be even up to 3.8%.
HOW TO MONITOR PATIENTS WHO HAVE  
SUFFERED APE IN ORDER NOT TO MISS CTEPH?
The monitoring of anatomical lesions in the pulmonary vessels 
and of the pulmonary haemodynamics in patients who have suf-
fered an episode of APE with pulmonary hypertension provides 
evidence that both of the above pathological components of 
CTEPH behave in a different and non-parallel manner in indi-
vidual patients. In the first 6 weeks after the embolic episode 
resolution of changes in the follow-up computed tomography 
scan is seen in a mere 32% of the patients [3], while pulmonary 
blood pressure normalises in half that time in as many as about 
90% of the patients [4]. The persistence of residual embolic 
changes in imaging studies can be expected in 57% of the pa-
tients at 6 months and 52% of the patients at 11 months after 
the episode of APE [5], which is in stark contrast to the very 
low prevalence of CTEPH. This suggests that there is no need 
to monitor post-APE residual embolic lesions using imaging 
techniques in order to identify patients at risk of CTEPH [6].
It seems, however, justified to monitor pulmonary blood 
pressure values in these patients. In the past, at facilities where 
pulmonary angiography was the principal tool for the diagno-
sis of APE, pulmonary blood pressure values during an APE 
episode were determined “by the way” during concomitant 
pulmonary haemodynamic study. Now, however, that this role 
has been taken over by imaging studies that no longer require 
pulmonary artery catheterisation, routine invasive measure-
ment of pulmonary pressures — although it is the only method 
that provides fully reliable measurements — can no longer 
be recommended. Pulmonary pressure should initially be 
estimated by non-invasive methods by echocardiography, an 
imaging modality in which more and more advanced equip-
ment is available. By measuring the pressure gradient across 
the tricuspid valve one can calculate pulmonary artery systolic 
pressure (PASP) from the modified Bernoulli formula. Alterna-
tively, other echocardiographic signs suggestive of pulmonary 
hypertension are looked for. These data, obtained from the 
echocardiogram, form the basis of the current ESC recommen-
dations for estimating the presence of pulmonary hypertension 
(Table 1). They distinguish the following categories: pulmonary 
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hypertension unlikely (PASP £ 36 mm Hg and no additional 
echocardiographic variables suggestive of pulmonary hyper-
tension), pulmonary hypertension possible (either PASP £ 
£ 36 mm Hg with additional echographic variables suggestive 
of pulmonary hypertension or PASP of 37–50 mm Hg with 
or without additional echocardiographic variables suggestive 
of pulmonary hypertension) and pulmonary hypertension 
likely (PASP > 50 mm Hg with or without additional echo-
cardiographic variables suggestive of pulmonary hypertension) 
[7]. The above echocardiographic data are also necessary in 
order to estimate the risk of in-hospital/30-day mortality in 
a patient with APE [8].
A PROPOSAL OF AN ALGORITHM  
FOR THE DIAGNOSIS AND TREATMENT  
OF CTEPH (FIG. 1)
Can the value of pulmonary pressure determined during an 
APE episode be predictive of future development of CTEPH? 
Numerous observational studies provide evidence that nor-
mal pulmonary pressure in this period indicates that this is 
not possible, provided the APE does not recur. Grifoni et al. 
[9] conducted an observational study in which they found 
no pulmonary hypertension on follow-up echocardiography 
at discharge in any of the 155 patients admitted with APE 
without the signs of pulmonary hypertension. Pulmonary 
hypertension did not develop in any of these patients over 
1 year of echocardiographic follow-up in patients with APE 
and baseline PASP < 40 mm Hg investigated by Ribeiro et al. 
[10] and at our facility [11]. It therefore seems that patients 
with APE but without the signs of pulmonary hypertension in 
the baseline echocardiogram do not need to be monitored 
for pulmonary hypertension in the future, and the duration 
of anticoagulant treatment should be determined on the 
basis of the current recommendations for the management 
of APE [8]. It should be emphasised that a sufficiently long 
duration of anticoagulation markedly decreases the risk of 
APE recurrences. Although the assessment of the impact of 
recurrences on the appearance or worsening of pulmonary 
hypertension in patients on anticoagulation varies [10–12], 
the risk of pulmonary hypertension during an APE recurrence 
largely increases when anticoagulation is discontinued [13].
Further echocardiographic monitoring of pulmonary 
pressure seems necessary in patients with APE and “likely” 
pulmonary hypertension but also in those in whom pulmonary 
hypertension is considered “possible” (i.e. even when PASP 
does not exceed 37 mm Hg but other signs suggestive of pul-
monary hypertension are present). Adopting such a cautious 
procedure seems justified, so that patients who might develop 
CTEPH in the future are not “missed”, given the fact that 
pulmonary pressure is monitored using echocardiography, i.e. 
a diagnostic method that is less reliable than haemodynamic 
studies. It is commonly recognised that echocardiographically 
determined pulmonary pressure values may be underesti-
mated (although this is usually the case with higher values) 
[14] and that there are discrepancies as to the upper limit of 
normal PASP [15]. Serial echocardiographic measurements 
of pulmonary pressure in patients with a recent history of 
an embolic event show that in most patients, whatever the 
baseline value, the pressure starts to decrease after initiation of 
anticoagulation [10, 11, 13] and that the pulmonary pressure 
reduction does not seem to be greater after using fibrinolytic 
treatment [10, 11]. However, the higher the baseline PASP, 
the higher the risk of non-normalisation [10, 11, 13]. Pa-
tients with baseline PASP values exceeding 50 mm Hg are at 
a 3-fold higher risk of chronic pulmonary hypertension [10]. 
On the other hand, pulmonary hypertension may completely 
resolve even in patients with the so-called subacute massive 
pulmonary embolism, which refers to APE recurrences that 
last 2–8 weeks and in which pre-anticoagulation PASP usually 
exceeds 70 mm Hg [16, 17].
Pulmonary pressure should also be monitored echocar-
diographically in patients in whom CTEPH develops accord-
ing to another scenario than that in patients who have been 
diagnosed with APE and who have received treatment for it. 
In a study by Lang [18], 63% of the 142 consecutive patients 
with CTEPH the disease had not started with the clinical 
manifestations of venous thromboembolism. These CTEPH 
cases might have developed as a result of undiagnosed and 
untreated clinically overt, subclinical or latent episodes of 
APE [19]. Meignan et al. [20] demonstrated that latent pul-
monary embolism may develop in up to 50% of the patients 
with proximal deep vein thrombosis. In these patients, the 
time between the undiagnosed embolic episode and the 
development of the first clinical manifestations (the so-called 
“honeymoon period”) may last many years [21]. It is not until 
the patient experiences increasing exertional dyspnoea and 
reduced exercise tolerance and until echocardiography shows 
signs of pulmonary hypertension that further evaluation of 
Table 1. Simplified criteria of probability of pulmonary hyper-
tension according to ESC [7] assuming a normal right atrial 
pressure of 5 mm Hg
Pulmonary hypertension 
unlikely
PASP £ 36 mm Hg and no additional 




PASP £ 36 mm Hg but presence of  
additional echocardiographic variables 
suggestive of pulmonary hypertension
or
PASP 37–50 mm Hg with/without 
additional echocardiographic variables 
suggestive of pulmonary hypertension
Pulmonary hypertension 
likely 
PASP > 50 mm Hg with/without ad-
ditional echocardiographic variables 
suggestive of pulmonary hypertension
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the latter is initiated [22]. If the imaging studies performed in 
these patients show thrombotic changes, then the presence 
of symptoms associated with pulmonary hypertension for 
more than 8 weeks coupled with the absence of recurrent 
embolisms during this period (which principally rules out 
the diagnosis of the so-called subacute massive pulmonary 
embolism) allows one to establish the diagnosis of CTEPH. 
However, our observations show that despite many years of 
a history suggestive of incipient pulmonary hypertension it 
should not be considered chronic, establishing the preliminary 
diagnosis of CTEPH, as after the initiation of anticoagulation 
the pressure decreases and even normalises [22, 23]. This is 
an argument to support the use of the same diagnostic algo-
rithm in this group of patients as in patients with pulmonary 
hypertension following APE.
So what should we call pulmonary hypertension that 
persists after a clinically overt or latent episode of APE 
but normalises after the initiation of anticoagulation in 
most of the patients? It seems that it should be referred 
to as persistent thromboembolic pulmonary hypertension 
(PTEPH) [12, 13]. Only in certain cases, PTEPH develops 
into CTEPH. As may be concluded from the serial echocar-
diographic measurements performed by Ribeiro et al. [10], 
PTEPH starts to develop into CTEPH on the sixth week after 
initiation of anticoagulant treatment. Around that time, in 
most patients, pulmonary hypertension enters the stabilisa-
tion phase without further decreasing in the later period. 
The presence of the signs of pulmonary hypertension in 
a follow-up echocardiogram after this period warrants 
the suspicion of CTEPH and a referral of these patients to 
reference centres where it is possible to perform haemo-
dynamic studies of the pulmonary circulation to reliably 
confirm the diagnosis. The clinical experience suggests, 
however, that the follow-up echocardiography and, pos-
sibly, also the haemodynamic study should be performed 
after 3 months rather than 6 weeks. In this case, if CTEPH 
is diagnosed and the patient is qualified for pulmonary 
endarterectomy, 3-month anticoagulation is advocated 
by cardiac surgeons to avoid perioperative embolic recur-
rences [24]. The correctness of the selection of this period 
Figure 1. A proposal of an algorithm for the diagnosis and treatment of thromboembolic pulmonary hypertension; CT — com-
puted tomography; CTEPH — chronic thromboembolic pulmonary hypertension; MPAP — mean pulmonary artery pressure; 
NYHA — The New York Heart Association; PASP — pulmonary artery systolic pressure; PTEPH — persistent thromboembolic 
pulmonary hypertension
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is confirmed by clinical observations, which also indicate 
that referrals for haemodynamic studies should be made in 
the case of those patients whose echocardiograms obtained 
at 3 months into anticoagulation reveal “likely” pulmonary 
hypertension with a PASP exceeding 50 mmHg [10, 11]. 
De Perrot et al. [11] showed progression of PASP in these 
patients over the further 6–12 months. This progression, 
provided there are no recurrences of APE, does not seem 
to occur in patients with “possible” pulmonary hypertension 
in follow-up echocardiography performed after 3 months 
of anticoagulation [12]. In some of these patients, further 
observation revealed a decrease or even normalisation of 
pulmonary hypertension [11, 13]. It therefore seems justified 
to uphold the diagnosis of PTEPH in patients with “possible” 
pulmonary hypertension following 3 months of anticoagula-
tion. These patients should continue anticoagulation and 
undergo a follow-up echocardiogram 6 months later. The 
persistence of the signs of pulmonary hypertension (“likely” 
or “possible”) after this period should prompt one to verify 
it in a haemodynamic study of the pulmonary circulation. 
However, the absence of echocardiographic signs of pul-
monary hypertension (unlikely pulmonary hypertension) 
merely requires anticoagulation to be performed in ac-
cordance with the principles of secondary prevention of 
thrombosis. These patients, provided they do not develop 
recurrent embolisms, most likely do not need to have their 
pulmonary pressure monitored any further.
As mentioned above, pulmonary hypertension can only 
be confirmed by invasive haemodynamic examination of the 
pulmonary circulation. All those patients, once the diagnosis 
has been confirmed, require indefinite anticoagulant therapy. 
The demonstration of proximal embolic lesions, accessible to 
the cardiac surgeon, in pulmonary angiography and/or other 
imaging studies allows to qualify patients with confirmed pul-
monary hypertension for pulmonary endarterectomy, which 
is the treatment of choice and leads to spectacular clinical 
outcomes [25]. Patients who are not eligible for this procedure 
may be offered specific vasodilator treatment or lung and heart 
transplantation. A proposal of an algorithm for the manage-
ment of patients with confirmed CTEPH has been presented 
elsewhere [26]. Patients most eligible for urgent pulmonary 
endarterectomy include those with the worst prognosis in 
whom MPAP exceeds 40 mm Hg [27]. Clinical observations 
of patients with moderate pulmonary hypertension, with 
MPAP exceeding 30 mm Hg, who refused to undergo surgery 
indicate that the clinical course of these patients varies but is 
generally unfavourable [28, 29]. For this reason this group of 
patients should be qualified for pulmonary endarterectomy 
[30], and the experiences of Polish and foreign centres suggest 
to perform the procedure in patients in a low NYHA functional 
class and coexistent peripheral embolic lesions [25, 30, 31]. 
In these patients, pulmonary hypertension, often worsens 
despite anticoagulation with time and decreases only in the 
terminal stage of right ventricular dysfunction.
However, not all the patients with haemodynamically 
confirmed pulmonary hypertension and with embolic le-
sions accessible to the cardiac surgeon must undergo surgery. 
Observations of patients with mild CTEPH and a MPAP not 
exceeding 30 mm Hg and with the so-called borderline pul-
monary hypertension (MPAP 21–24 mm Hg) indicate that 
long-term prognosis is favourable [23, 28, 29], and a prospec-
tive 3-year observation of 10 such anticoagulated patients at 
our facility has shown a reduction in pulmonary pressure, 
improvement of the NYHA functional class and improve-
ment of exercise tolerance in all of these patients [23]. In 9 of 
these patients, pulmonary hypertension was assessed echo-
cardiographically 3 years later as being “unlikely”, although 
this has not been verified with the reliable haemodynamic 
study. It seems that these patients should be regularly assessed 
echocardiographically and clinically and referred for surgery 
only if their pulmonary pressure rises, their NYHA functional 
class worsens, their exertional dyspnoea exacerbates or their 
exercise tolerance decreases. 
CONCLUSIONS
Pulmonary hypertension, which often accompanies overt 
embolic episodes or develops in the course of clinically latent 
form of this disease, rapidly decreases and usually resolves 
within 6 weeks after initiation of anticoagulation. However, 
the course of this period, which may be referred to as per-
sistent thromboembolic pulmonary hypertension (PTEPH), 
varies from patient to patient and is often prolonged in patients 
with high baseline pulmonary hypertension. PTEPH only oc-
casionally develops into chronic thromboembolic pulmonary 
hypertension (CTEPH). In our diagnostic and therapeutic 
algorithm, based on nearly 20 years of published observations, 
the strategic role in the monitoring of pulmonary hypertension 
— from the initial examination till the resolution or establish-
ment of chronicity of pulmonary hypertension — has been 
attributed to echocardiography. Echocardiographic suspicion 
of CTEPH established after at least 3 months of anticoagula-
tion must be confirmed by an invasive haemodynamic study 
of the pulmonary circulation. All the patients with CTEPH 
require indefinite anticoagulation therapy. Demonstration 
of a MPAP exceeding 30 mm Hg suggests that these patients 
should undergo surgery and/or drug treatment.
The natural history of thromboembolic pulmonary hyper-
tension presented above, which has formed the basis for the 
development of an original algorithm for the diagnosis and 
treatment, should facilitate the decision to refer patients with 
suspected CTEPH to reference centres and those with con-
firmed CTEPH and accessible embolic lesions for pulmonary 
endarterectomy. It should also prevent patients with PTEPH 
from undergoing surgery.
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